Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (VR1) and uses thereof

1. A method of treating a disorder selected from the group consisting of pain, urinary incontinence, and bladder overactivity in a host mammal in need of such treatment comprising administering to the host mammal a therapeutically effective amount of a compound of formula (I):

or a pharmaceutically acceptable salt thereof, wherein

- - - is absent or a covalent bond;

X 1 is CR 1 ;

X 2 is CR 2 ;

X 3 is N;

X 4 is CR 4 ;

X 5 is selected from N and CH 2 ;

X 6 is selected from O, NH and S;

Z 1 is selected from O, NH and S;

Z 2 is absent or selected from NH and O;

L is selected from aryl, alkenylene, alkylene, alkynylene, cycloalkylene, heterocycle, —(CH 2 ) m O(CH 2 ) n —, —N(H)O—, and —NHNH— wherein the left end of —(CH 2 ) m O(CH 2 ) n — and —N(H)O— is attached to Z 2 and the right end is attached to R 7 ;

provided that when Z 2 is NH or O then L is other than —N(H)O— or —NHNH—;

m and n are each independently 1-6;

R 1 , R 3 and R 5 are each independently selected from hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonyloxy, alkylthio, alkynyl, amines, carboxy, carboxyalkyl, cyano, cyanoalkyl, cycloalkyl, cycloalkylalkyl, ethylenedioxy, formyl, formylalkyl, haloalkoxy, haloalkyl, haloalkylthio, halogen, hydroxy, hydroxyalkyl, methylenedioxy, mercapto, mercaptoalkyl, nitro, (CF 3 ) 2 (HO)C—, R B S(O) 2 R A N—, R A OS(O) 2 —, R B —S(O) 2 —, Z A Z B N—, (Z A Z B N)alkyl, (Z A Z B N)carbonyl, (Z A Z B N)alkylcarbonyl and (Z A Z B N)sulfonyl, wherein Z A and Z B are each independently selected from hydrogen, alkyl, alkylcarbonyl, formyl, aryl and arylalkyl;

R 2 and R 4 are each independently selected from the group consisting of hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonyloxy, alkylthio, alkynyl, amines, carboxy, carboxyalkyl, cyano, cyanoalkyl, cycloalkyl, cycloalkylalkyl, ethylenedioxy, formyl, formylalkyl, haloalkoxy, haloalkyl, haloalkylthio, halogen, hydroxy, hydroxyalkyl, methylenedioxy, mercapto, mercaptoalkyl, nitro, (CF 3 ) 2 (HO)C—, R B S(O) 2 R A N—, R A OS(O) 2 —, R B —S(O) 2 —, Z A Z B N—, (Z A Z B N)alkyl, (Z A Z B N)carbonyl, (Z A Z B N)alkylcarbonyl, (ZAZ B N)sulfonyl, (Z A Z B N)C(═NH)—, (Z A Z B N)C(═NCN)NH—, and (Z A Z B N)C(═NH)NH—;

R A is selected from hydrogen and alkyl;

R B is selected from alkyl, aryl and arylalkyl;

R 6 is absent or selected from hydrogen and alkyl;

provided that R 6 is absent when X 5 is CH 2 and R 6 is selected from hydrogen and alkyl when X 5 is N; and

R 7 is selected from hydrogen, aryl and heterocycle.

2. The method of claim 1 wherein the disorder is pain.

3. The method of claim 1 wherein the disorder is urinary incontinence.

4. The method of claim 1 wherein the disorder is bladder overactivity.

5. The method of claim 1 wherein the compound of formula (I) is selected from the group consisting of:

1-(4-chloro-benzyl)-3-(2-methyl-thieno[2,3-c]pyridin-3-yl)-urea;

1-(2,4-dichloro-benzyl)-3-(2-methyl-thieno[2,3-c]pyridin-3-yl)-urea;

1-(3,4-dichloro-benzyl)-3-(2-methyl-thieno[2,3-c]pyridin-3-yl)-urea;

1-(2-methyl-thieno[2,3-c]pyridin-3-yl)-3-[1-methyl-1-(4-trifluoromethylphenyl)-ethyl]-urea;

1-(2,3-difluoro-4-trifluoromethyl-benzyl)-3-(2-methyl-thieno[2,3-c]pyridin-3-yl)-urea;

1-(2,4-bis-trifluoromethyl-benzyl)-3-(2-methyl-thieno[2,3-c]pyridin-3-yl)-urea;

1-(2-chloro-4-trifluoromethyl-benzyl)-3-(2-methyl-thieno[2,3-c]pyridin-3-yl)-urea;

1-(4-bromo-3-methyl-benzyl)-3-(2-methyl-thieno[2,3-c]pyridin-3-yl)-urea;

1-(4-trifluoromethoxy-benzyl)-3-(2-methyl-thieno[2,3-c]pyridin-3-yl)-urea;

1-(3-trifluoromethylbenzyl)-3-(2-methyl-thieno[2,3-c]pyridin-3-yl)-urea;

1-(3-trifluoromethoxybenzyl)-3-(2-methyl-thieno[2,3-c]pyridin-3-yl)-urea;

(2-methyl-thieno[2,3-c]pyridin-3-yl)-carbamic acid 4-trifluoromethyl-benzyl ester;

(2-methyl-thieno[2,3-c]pyridin-3-yl)-carbamic acid 4-trifluoromethoxy-benzyl ester;

(2-methyl-thieno[2,3-c]pyridin-3-yl)-carbamic acid 4-trifluoromethylsulfanyl-benzyl ester;

1-benzyl-3-(2-methyl-thieno[2,3-c]pyridin-3-yl)-urea;

1-(2-methyl-benzyl)-3-(2-methyl-thieno[2,3-c]pyridin-3-yl)-urea;

1-(3-methyl-benzyl)-3-(2-methyl-thieno[2,3-c]pyridin-3-yl)-urea;

1-(4-methyl-benzyl)-3-(2-methyl-thieno[2,3-c]pyridin-3-yl)-urea;

1-(3-Fluoro-5-trifluoromethyl-benzyl)-3-(2-methyl-thieno[2,3-c]pyridin-3-yl)-urea;

1-(4-methoxy-benzyl)-3-(2-methyl-thieno[2,3-c]pyridin-3-yl)-urea;

1-(2-fluorobenzyl)-3-(2-methyl-thieno[2,3-c]pyridin-3-yl)-urea;

1-(3-fluorobenzyl)-3-(2-methyl-thieno[2,3-c]pyridin-3-yl)-urea;

1-(4-fluorobenzyl)-3-(2-methyl-thieno[2,3-c]pyridin-3-yl)-urea;

1-(2-chlorobenzyl)-3-(2-methyl-thieno[2,3-c]pyridin-3-yl)-urea;

1-(3-chlorobenzyl)-3-(2-methyl-thieno[2,3-c]pyridin-3-yl)-urea;

1-(2-bromobenzyl)-3-(2-methyl-thieno[2,3-c]pyridin-3-yl)-urea;

1-(3-bromobenzyl)-3-(2-methyl-thieno[2,3-c]pyridin-3-yl)-urea;

1-(2-methyl-thieno[2,3-c]pyridin-3-yl)-3-naphthalen-1-ylmethylurea;

1-(2,3-dimethylbenzyl)-3-(2-methyl-thieno[2,3-c]pyridin-3-yl)-urea;

1-(2,5-dimethylbenzyl)-3-(2-methyl-thieno[2,3-c]pyridin-3-yl)-urea;

1-(3,4-dimethylbenzyl)-3-(2-methyl-thieno[2,3-c]pyridin-3-yl)-urea; and

1-(2-methyl-thieno[2,3-c]pyridin-3-yl)-3-(5-piperidin-1-yl-indan-1-yl)-urea.